Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.